Next Article in Journal
EOB-MR Based Radiomics Analysis to Assess Clinical Outcomes following Liver Resection in Colorectal Liver Metastases
Next Article in Special Issue
Synthetic Vulnerabilities in the KRAS Pathway
Previous Article in Journal
Radiotherapy Is Associated with an Accelerated Risk of Carotid Atherosclerosis in Patients with Nasopharyngeal Carcinoma: A Nine-Year Prospective Follow-Up Study
Previous Article in Special Issue
Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review
 
 
Review

The BRCA Gene in Epithelial Ovarian Cancer

1
Department of Medical Oncology, Clínica Universidad de Navarra, 28027 Madrid, Spain
2
Solid Tumor Program (CIMA), Clínica Universidad de Navarra, 31008 Pamplona, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Bo Ruben Rueda
Cancers 2022, 14(5), 1235; https://doi.org/10.3390/cancers14051235
Received: 15 January 2022 / Revised: 20 February 2022 / Accepted: 21 February 2022 / Published: 27 February 2022
(This article belongs to the Special Issue Oncogenes in Cancer)
Epithelial ovarian cancer (EOC) is still the most lethal gynecological cancer. In the recent years, the germline alterations in breast cancer 1 (gBRCA1) and breast cancer 2 (gBRCA2) genes are of key importance not only for genetic counseling purposes, but for its therapeutic implications, as well as somatic mutations, for the latter. The integration of poly-(ADP ribose) polymerase inhibitors (PARPis) as part of the therapeutic options has changed EOC natural history.
Epithelial ovarian cancer (EOC) is still the most lethal gynecological cancer. Germline alterations in breast cancer 1 (gBRCA1) and breast cancer 2 (gBRCA2) genes have been identified in up to 18% of women diagnosed with EOC, and somatic mutations are found in an additional 7%. Testing of BRCA at the primary diagnosis of patients with EOC is recommended due to the implications in the genomic counseling of the patients and their families, as well as for the therapeutic implications. Indeed, the introduction of poly-(ADP ribose) polymerase inhibitors (PARPis) has changed the natural history of patients harboring a mutation in BRCA, and has resulted in a new era in the treatment of patients with ovarian cancer harboring a BRCA mutation. View Full-Text
Keywords: BRCA; PARPi; epithelial ovarian cancer; hereditary breast and ovarian cancer BRCA; PARPi; epithelial ovarian cancer; hereditary breast and ovarian cancer
Show Figures

Figure 1

MDPI and ACS Style

Sánchez-Lorenzo, L.; Salas-Benito, D.; Villamayor, J.; Patiño-García, A.; González-Martín, A. The BRCA Gene in Epithelial Ovarian Cancer. Cancers 2022, 14, 1235. https://doi.org/10.3390/cancers14051235

AMA Style

Sánchez-Lorenzo L, Salas-Benito D, Villamayor J, Patiño-García A, González-Martín A. The BRCA Gene in Epithelial Ovarian Cancer. Cancers. 2022; 14(5):1235. https://doi.org/10.3390/cancers14051235

Chicago/Turabian Style

Sánchez-Lorenzo, Luisa, Diego Salas-Benito, Julia Villamayor, Ana Patiño-García, and Antonio González-Martín. 2022. "The BRCA Gene in Epithelial Ovarian Cancer" Cancers 14, no. 5: 1235. https://doi.org/10.3390/cancers14051235

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop